Published 2012-07-02
Ahmad Zulfan Hendri Danarto HR


Objective: To know the relationship between p53 expression and prostate specific antigen (PSA) serum level in prostate cancer patients. Material & method: Specimens were studied from patients with pathological diagnosis of prostate cancer in Sardjito Hospital Yogyakarta during 2007 to 2008. The p53 expression was measured by immunohistochemical staining. The stains were done in Department of Anatomical Pathology and examined by a pathologist. The relationship between p53 mutated expression and PSA serum level were analyzed with correlation coefficient (rs). Results: There were 29 patients included in this study. The mean age was 66,34 ± 8,15 (50 - 83) years old. The mean PSA serum level was 165,98 ± 269,208 (1,4 – 1051) ng/ml. The mean number of p53 expression was 111,38 ± 94,30 (16 – 396). There was positive correlation between p53 expression and increasing PSA serum level in the prostate cancer patients (rs + 0,497; p = 0,006). Conclusion: P53 expression was positively correlated with increasing PSA serum level.Keywords: Prostate cancer, p53 expression, PSA serum level.



Steven P. Balk, Yoo-Joung Ko, Glenn J. Bubley. Biology of prostate-specific antigen. Journal of Clinical Oncology. 2003; 28(2): 383–91.

Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen (PSA) in the early detection of prostate cancer: Results of a multicentre clinical trial of 6,630 men. J Urol. 1994; 151(5): 1283-90.

Gretzer MB, Partin AW. Prostat cancer tumor marker. In: Wein, Kavoussi, Novick, Partin, Peter (ed). Campbell – Walsh Urology. 9th ed. Saunders; 2007.

Read AP, Strachan T. Cancer genetics. In: Human molecular genetics 2. New York: Wiley; 1999.

Papadopoulos I, Rudolph P, Wirth B, Jacobsen K. P53 expression, proliferation marker kis5, DNA content and serum PSA: Possible biopotential markers in human prostatic cancer. Urology. 1996; 48(2).

Gotthieb TM, Oren M. Biochemical and Biophysics Acta. 1996; 1287: 77–102.

Gurova KV, Roklin, Krivokrysenko, Chumakov PM, Cohen. Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene. 2002; 21: 153–7.

Shurbaji, Kalbfleisch JH, Thurmond ST. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Human Pathology. 1995; 26(1).

Meyer FJ, Gumerlock PH, Chi SG. Very frequent p53 mutations in metastatics prostate carcinoma and in matched primary tumors. Cancer. 1998; 83: 2534-9.

Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy: The Johns Hopkins Experience after 10 years. Urol Clin North Am. 1993; 20: 713–25.

July 2012 Vol. 19 No. 2
Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University